Biotech news that matter for investors: CoLucid Pharmaceuticals (CLCD), Idera Pharmaceuticals (NASDAQ:IDRA) – The Voice Registrar

Biotech news that matter for investors: CoLucid Pharmaceuticals (CLCD), Idera Pharmaceuticals (NASDAQ:IDRA)The Voice RegistrarIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) on August 24, 2016 announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform.and more »

Read More

Positive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of Study – IBD News Today

IBD News TodayPositive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of StudyIBD News Today“These data support the notion that GED-0301, a potential first-in-class oral antisense therapy, may target an underlying cause of Crohn’s disease, rather than simply improving symptoms.” GED-0301 takes an unusual approach to treating Crohn’s, using …

Read More

Antisense Therapeutics Limited Pipeline Reviews and Clinical Trail Assessment 2016- Market Share, and Forecasts – Medgadget (blog)

Antisense Therapeutics Limited Pipeline Reviews and Clinical Trail Assessment 2016- Market Share, and ForecastsMedgadget (blog)MarketResearchStore159 The Market research comprehensive data on Antisense Therapeutics Limited Market Product Pipeline Review, 2016, is well organized and easily readable. This group is engage in a wide range of other fields and businesses like …and more »

Read More

Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s … – Business Wire (press release)

Review FortuneCelgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s …Business Wire (press release)“These data support the notion that GED-0301, a potential first-in-class oral antisense therapy, may target an underlying cause of Crohn’s disease, rather than simply improving symptoms.” Full data from the 12-week timepoint have been submitted for …Celgene’s Crohn’s disease candidate GED-0301 shows encouraging action in early-stage studySeeking Alphaall 34 news articles »

Read More

Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference – Yahoo Finance

Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment ConferenceYahoo Finance06, 2016 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced …and more »

Read More

Favorable Government Initiatives And Awareness Programs To Encourage Growth Of Global Antisense RNAi … – Medgadget (blog)

Favorable Government Initiatives And Awareness Programs To Encourage Growth Of Global Antisense RNAi …Medgadget (blog)MrrBiz41 A new market intelligence study has been added by MarketResearchReports.biz to its comprehensive collection of research studies. The 124-page research report, titled “PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics …

Read More

Antisense considers options – NEWS.com.au

Antisense considers optionsNEWS.com.auAntisense Therapeutics will assess the progress of current partnering and non-dilutive funding initiatives along with a number of strategic options including potential new growth opportunities to complement the companys existing product pipeline, core …

Read More

Wedbush Positive on Idera Pharmaceuticals Inc (IDRA); Sings the Praises of 3GA Technology – Smarter Analyst

iStreetWireWedbush Positive on Idera Pharmaceuticals Inc (IDRA); Sings the Praises of 3GA TechnologySmarter AnalystIf 3GA is able to take hold of the beneficial tissue distribution of antisense, yet while retaining the same power and tolerability that RNAi advocates, the firm could have a real clinical catalyst on its hands. The analyst highlights that Idera built …Idera Pharmaceuticals Inc. (IDRA) Receives Outperform Rating from …Community Financial NewsIdera Pharmaceuticals (NASDAQ:IDRA) presents pre-clinical data …Benchmark MonitorWatchful Active Movers- Jacobs Engineering (NYSE:JEC), Aehr Test …Seneca GlobeStreet Wise Report (press release) (blog)all 15 news articles »

Read More

No rotten tomatoes—Can genetic engineering help create a tastier but still hardy fruit? – Genetic Literacy Project

Genetic Literacy ProjectNo rotten tomatoes—Can genetic engineering help create a tastier but still hardy fruit?Genetic Literacy ProjectThe enzyme polygalacturonase, which was the target of Flavr Savr antisense technology because of its ability to break down pectin and encourage ripening, remains the target of genetic and chemical studies. A group including tomato antisense pioneer Don …

Read More

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology – Yahoo Finance

iStreetWireIdera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense TechnologyYahoo FinanceIn the presentation, entitled “Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides,” Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the …Recommended Momentum ‘How’ and ‘Why’: Idera Pharmaceuticals …Street Wise Report (press release) (blog)Idera Pharmaceuticals (NASDAQ:IDRA) presents pre-clinical data …Benchmark MonitorWatchful Active Movers- Jacobs Engineering (NYSE:JEC), Aehr Test …Seneca GlobeSmarter Analyst -Community Financial Newsall 15 news articles »

Read More

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology – Nasdaq

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense TechnologyNasdaqIn the presentation, entitled “Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides,” Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the …Idera Pharmaceuticals Inc. (IDRA) Receives “Outperform” Rating from WedbushCommunity Financial NewsWedbush Morgan Reiterates Idera Pharmaceuticals Outperform Rating with $6 PT (NASDAQ:IDRA)Consumer Eagleall 4 news articles »

Read More

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology – GlobeNewswire (press release)

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense TechnologyGlobeNewswire (press release)In the presentation, entitled “Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides,” Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the …

Read More

Favorable Government Initiatives and Awareness Programs to Encourage Growth of Global Antisense RNAi … – Digital Journal

Favorable Government Initiatives and Awareness Programs to Encourage Growth of Global Antisense RNAi …Digital JournalThe 124-page research report, titled “PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market Analysis,” offers a detailed analysis, emphasizing on the current trends and growth prospects in the market. The research report has …

Read More

Revenue Update on Bio-Path Holdings Inc(NASDAQ:BPTH) – Trade … – Trade Calls

Revenue Update on Bio-Path Holdings Inc(NASDAQ:BPTH) – Trade …Trade CallsBio-Path Holdings Inc(NASDAQ:BPTH) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 10, 2016.Next Weeks Broker Price Targets For Bio-Path Holdings (BPTH …Fiscal StandardBio Path Holdings DE (NASDAQ:BPTH) Sellers Covered 8.01% of …Consumer Eagleall 4 news articles »

Read More

Piper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead – Smarter Analyst

Smarter AnalystPiper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future AheadSmarter AnalystWith the biotech firm’s SMA BIIB-partnered antisense program (nusinersen) now on “fast track towards commercialization” following a successful ENDEAR study, Schimmer considers IONS as a “top mid-cap pick,” and subsequently, the analyst reiterates an …and more »

Read More

Combining forces against Influenza A – Science Daily

Combining forces against Influenza AScience DailyA new avenue being explored includes antiviral drugs created using so-called antisense oligonucleotides (AONs) — synthetic polymers that can block disease progression by altering viral RNA activity. “The next Influenza A pandemic is inevitable, given …

Read More